ASAnna Sachoulidou

Anna Sachoulidou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Sachoulidou has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tumor Mutational Landscape and Its Correlation with Histopathological Characteristics in Breast Cancer

    by Eirini Papadopoulou, Maroulio Stathoulopoulou, Maria Matiatou, Panagiotis Karathanasis, Xenofon Xenakis, Grigorios Pesmatzoglou, Ioannis Fyssas, Konstantinos Louis, Dimitrios Maniatis, Anastasia Ekmektzoglou, et al.

    In breast cancer, current knowledge of the associations between clinicopathologic characteristics, genetic changes, and subtype-specific patterns remain unclear. This research investigated how pathological and clinical variables affect the actionability of NGS-based tumor molecular data. Materials and methods: 227 breast cancer patients referred to Genekor’s laboratory for tumor molecular profile analysis were included in the study. Pathology records, available in all cases, were used to assess critical clinicopathological features including HER2, ER, PR, Ki67, grade, metastatic site, and age. A 1021 gene NGS-based multigene panel was utilized to assess tumors’ biology alongside tumor mutational burden (TMB) and microsatellite instability (MSI) Results: Comprehensive genomic profiling revealed that 95.6% of the patients harbored at least one oncogenic or likely oncogenic alteration, highlighting the high diagnostic yield of NGS-based testing. Distinct subtype-specific patterns were observed: HR+/HER2-tumors were enriched for PIK3CA and ESR1 gene alterations, while Triple Negative Breast Cancer (TNBC) was dominated by TP53 alterations. Clinically actionable alterations were most common in HR+/HER2-tumors (~60% on-label), whereas TNBC more often harbored off-label or trial-associated targets. The inclusion of tumor-agnostic biomarkers (TMB/MSI) increased on-label actionability up to 64.5% in ER−/PR+ tumors. primarily driven by TMB-high cases. Median TMB values were low, and age was the only independent predictor. Furthermore, the presence of actionable alterations was significantly higher in metastatic tumors, and TP53 alterations were associated with aggressive tumor characteristics.Conclusions: Comprehensive NGS-based genomic profiling identifies clinically actionable alterations in over half of breast cancer patients, with substantial variability across molecular subtypes. The HR+/HER2-subtype demonstrates the highest prevalence of on-label actionable biomarkers. These findings support the routine implementation of comprehensive genomic profiling, especially in metastatic HER2-negative breast cancer, to guide precision oncology strategies and enable enrollment in biomarker-driven clinical trials.

  • Open Access

    Evaluating the Association of Ki-67 with Oncotype DX Recurrence Score in Early-Stage ER-Positive/HER2-Negative Breast Cancer

    by Dimitrios Dragoumis, George Kapetsis, Konstantinos Louis, Dimitrios Maniatis, Eleni Mpalampou, Konstantinos Bouloukos, Xenophon Xenakis, Nikolaos Papaioannou, Styliani Parpoudi, Grigorios Pesmatzoglou, et al.

    Background/Objectives: Ki-67 is widely used as an immunohistochemical marker of tumor proliferation in hormone receptor-positive (HR-positive), HER2-negative breast cancer, but its interpretation is limited by variability and uncertain concordance with genomic assays. The Oncotype DX® Recurrence Score (RS) is a validated multigene assay with established prognostic and predictive utility. This study evaluated the relationship between Ki-67 and RS in clinical practice. Methods: We retrospectively analyzed women in Greece with early-stage estrogen receptor-positive, HER2-negative breast cancer without distant metastasis (pM0) who underwent Oncotype DX testing between 2020 and 2023. Eligible patients were node-negative or postmenopausal with node-positive disease. RS was categorized as low (0–25) or high (>25). Ki-67 was assessed using binary (5–p < 0.001). After stratification, associations with RS were observed only in tumors with high Ki-67 expression, whereas no correlation was detected in low or intermediate groups. RS distributions differed significantly across Ki-67 strata. Overall concordance between Ki-67-based proliferation categories and RS-based genomic risk was 56.2%, with discordant cases in both directions. Conclusions: Ki-67 shows a modest association with Oncotype DX RS, but substantial discordance indicates Ki-67 should not substitute genomic testing in HR-positive/HER2-negative early breast cancer.

  • Open Access

    Evaluating the Association of Ki 67 with Oncotype DX Recurrence Score in Early-Stage ER Positive/HER2 Negative Breast Cancer

    by Dimitrios Dragoumis, George Kapetsis, Konstantinos Louis, Dimitrios Maniatis, Eleni Mpalampou, Konstantinos Bouloukos, Xenophon Xenakis, Nikolaos Papaioannou, Styliani Parpoudi, Grigorios Pesmatzoglou, et al.

    Background/Objectives Ki‑67 is widely used as an immunohistochemical marker of tumor proliferation in hormone receptor–positive (HR‑positive), HER2‑negative breast cancer, but its inter-pretation is limited by variability and uncertain concordance with genomic assays. The Oncotype DX® Recurrence Score (RS) is a validated multigene assay with established prognostic and predictive utility. This study evaluated the relationship between Ki‑67 and RS in clinical practice. Methods We retrospectively analyzed women in Greece with early‑stage estrogen receptor–positive, HER2‑negative breast cancer without distant metastasis (pM0) who under-went Oncotype DX testing between 2020 and 2023. Eligible patients were node nega-tive or postmenopausal with node positive disease. RS was categorized as low (0–25) or high (>25). Ki‑67 was assessed using binary (< 20% vs ≥20%) and three‑tier (≤5%, >5%–< 30%, ≥30%) classifications. Associations were analyzed using correlation, con-cordance, and nonparametric methods. Results Among 2,967 patients, the median RS was 16, with similar distributions across nodal subgroups. Ki‑67 and RS demonstrated a moderate positive correlation as continuous variables (r = 0.42, p < 0.001). After stratification, associations with RS were observed only in tumors with high Ki‑67 expression, whereas no correlation was detected in low or intermediate groups. RS distributions differed significantly across Ki‑67 strata. Overall concordance between Ki‑67‑based proliferation categories and RS‑based ge-nomic risk was 56.2%, with discordant cases in both directions. Conclusions Ki‑67 shows a moderate association with Oncotype DX RS, but substantial discordance indicates it should not substitute genomic testing in HR‑positive/HER2‑negative early breast cancer.

  • Omission of Radiotherapy in Women >60 Years Old After Breast Conserving Surgery for Breast Cancer is Non-Inferior in Terms of Local Recurrence: A Retrospective Cohort Study

    by Anna Sachoulidou, Fani Apostolidou, Charalambos Fronis, Despoina Misailidou, Aichan Bozoglou, Themis Anastasia Tataridou, Aristomenis Ampatzoglou, Ioannis Galanis

    Local recurrence rate may show no significant differences between women aged 60 and older who receive breast-conserving surgery followed by radiotherapy and those in the same age group who undergo breast-conserving surgery without subsequent radiotherapy. Retrospective cohort study from a single practice with median follow-up time 44 months (interquartile range: 16, 82), comparing women older than 60 years old at diagnosis of breast cancer, treated with breast conserving surgery and either receiving or not receiving radiation therapy postoperatively. The primary endpoint was local recurrence difference between the two groups. Local recurrence did not differ significantly between the two groups in terms of radiotherapy or not [odds ratio (OR) 0.96, 95% confidence interval (CI) 0.89–1.02, Fisher’s exact test p = 0.388], nor between two age groups with cut-off at 65 years of age (OR: 0.99, 95% CI 0.92–1.07, Fisher’s Exact test p = 0.6). Local recurrence also did not differ when subgroups of age (60–65 years and >66 years) were considered. All patients received 5 years of hormonal therapy. Omission of radiotherapy in selected patients is not inferior to radiotherapy after breast conserving surgery in terms of preventing local recurrence.